Form 4: Contineum CSO Sells 4,170 Shares Under 10b5-1 Plan

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 4,170 shares of Class A Common Stock for a weighted average price of $12.2324 per share.

Summary

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc. (CTNM), sold 4,170 shares of Class A Common Stock.
• The transaction occurred on December 23, 2025, at a weighted average price of $12.2324 per share.
• The shares were sold in multiple transactions ranging from $12.00 to $12.38 per share.
• This sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025.
• Following the transaction, Mr. Lorrain directly owns 164,392 shares and indirectly owns 6,842 shares through his spouse.
• His indirect holdings include shares purchased via the Employee Stock Purchase Plan on May 15, 2025 (1,364 shares) and November 14, 2025 (1,580 shares).

Sentiment

Score: 5

Explanation: A neutral score is assigned as this is a routine insider sale under a 10b5-1 plan. While a sale reduces insider ownership, the pre-planned nature mitigates negative implications, and the officer retains significant holdings.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale not based on immediate insider information.
• The Chief Scientific Officer retains a significant direct and indirect beneficial ownership of 171,234 shares (164,392 direct + 6,842 indirect) after the sale, demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which solely reports an insider transaction.

Industry Context

This Form 4 filing reports a routine insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape. Insider sales, even pre-planned, are common in the biotechnology and pharmaceutical sectors as executives manage personal finances and diversify portfolios.

Comparison to Industry Standards

• This Form 4 filing reports a standard insider transaction under a 10b5-1 plan. Such plans are widely used across industries, including biotech, to allow insiders to sell shares without being accused of trading on material non-public information.
• The retention of a significant equity stake by the Chief Scientific Officer post-sale is also a common practice among executives in comparable companies, demonstrating continued commitment.

Related Party Transactions

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc., sold 4,170 shares of the company's Class A Common Stock. This is a direct transaction between an insider and the market.

Stakeholder Impact

• Shareholders: The sale by a key executive might be viewed with slight caution, though the 10b5-1 plan mitigates concerns about opportunistic selling. The executive still holds a substantial number of shares, maintaining alignment.
• Employees: No direct impact on employees is indicated by this transaction.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider sale by the Chief Scientific Officer under a 10b5-1 plan. While it reduces the insider's direct stake, the transaction is not indicative of new material information and the officer retains significant holdings. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Contineum Therapeutics, CTNM, Insider Sale, Form 4, Daniel S. Lorrain, Chief Scientific Officer, Stock Transaction, 10b5-1 Plan, Equity Sales